Martin Schepelmann
Group leader of the research group “Interdisciplinary Pathophysiology” at the Institute of Pathophysiology and Allergy Research, Medical University of Vienna, Austria.
Biography
Priv.-Doz. Mag. pharm. Dr. Martin Schepelmann is a group leader at the Institute for Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology, and Immunology, at the Medical University of Vienna, Austria. After studying Pharmacy at the University of Vienna, Dr. Schepelmann moved to the UK in 2011 to pursue a PhD in Physiology as Marie Skłodowska-Curie Fellow at Cardiff University (UK), in the group of Prof. Daniela Riccardi. After a 3-year postdoc in drug discovery in the group of Prof. Andrea Brancale, Dr. Schepelmann returned to Austria in 2017 and took up a position as senior postdoc at the Medical University of Vienna in the research group of Enikö Kallay. In June 2023, he successfully completed his Habilitation in Pathophysiology and started his own research group. His research interests include the role of the Calcium-Sensing Receptor in health and disease, the effects of aging and dietary measures on colitis and colorectal cancer, and the role of nucleic acid receptors in cancer. Due to his training as both a pharmacist and physiologist, as well as his work in drug discovery, Dr. Schepelmann is especially interested in “building bridges” bridges between these disciplines. Dr. Schepelmann was awarded many international and national prizes for his work, e.g. the American Society for Bone and Mineral Research Young Investigator Award, the Science Prize of the Austrian Society for Endocrinology and Metabolism, and “Researcher of the Month” of the Medical University of Vienna.
Dr. Schepelmann is the coordinator of the “eRaDicate” Doctoral Network, funded with more than € 2.5 Mio to train 11 PhD students in anti-cancer research and drug discovery all over Europe.